TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07058077: An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants With Heterozygous Familial Hypercholesterolemia

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 153 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$486,048

Rescue Site Savings

+$324,032

Unlock Full NCT07058077 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07058077 Rescue Dossier →